A high-content imaging assay for the quantification of the Burkholderia pseudomallei induced multinucleated giant cell (MNGC) phenotype in murine macrophages

BMC Microbiology

Volumn 14, Issue 1, 2014, Pages

  Pegoraro, Gianluca ^a,b,c   Eaton, Brett P ^a   Ulrich, Ricky L ^a   Lane, Douglas J ^a   Ojeda, Jenifer F ^a   Bavari, Sina ^a   Deshazer, David ^a   Panchal, Rekha G ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b PERKINELMER INC   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Burkholderia pseudomallei; High Content imaging; Macrophages; Multinucleated giant cells; phagocytosis

Indexed keywords

HISTONE DEACETYLASE INHIBITOR;

ARTICLE; BACTERIAL VIABILITY; BACTERIUM MUTANT; BURKHOLDERIA PSEUDOMALLEI; CELL MEMBRANE; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONTROLLED STUDY; DNA METHYLATION; FLUORESCENCE MICROSCOPY; GENE DELETION; GIANT CELL; HIGH CONTENT IMAGING ASSAY; HISTONE MODIFICATION; IMAGE ANALYSIS; IMMUNOFLUORESCENCE TEST; MACROPHAGE; MOLECULAR LIBRARY; NONHUMAN; PHENOTYPE; QUANTITATIVE ASSAY; SCREENING; SINGLE CELL ANALYSIS; STAINING; TYPE VI SECRETION SYSTEM;

ANIMALIA; BACTERIA (MICROORGANISMS); BURKHOLDERIA PSEUDOMALLEI; MURINAE; MYCOBACTERIUM TUBERCULOSIS; NEGIBACTERIA;

EID: 84901197044     PISSN: None     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/1471-2180-14-98     Document Type: Article

References (76)

1. Molecular insights into Burkholderia pseudomallei and Burkholderia mallei pathogenesis. Galyov EE, Brett PJ, DeShazer D, Annu Rev Microbiol 2010 64 495 517 10.1146/annurev.micro.112408.134030 20528691
2. Melioidosis in animals: a review on epizootiology, diagnosis and clinical presentation. Sprague LD, Neubauer H, J Vet Med B Infect Dis Vet Public Health 2004 51 305 320 10.1111/j.1439-0450.2004.00797.x 15525357 (Pubitemid 39533604)
3. Melioidosis: epidemiology, pathophysiology, and management. Cheng AC, Currie BJ, Clin Microbiol Rev 2005 18 383 416 10.1128/CMR.18.2.383-416.2005 15831829 (Pubitemid 40548298)
4. Melioidosis. White NJ, Lancet 2003 361 1715 1722 10.1016/S0140-6736(03) 13374-0 12767750 (Pubitemid 36577448)
5. Cutaneous melioidosis in a man who was taken as a prisoner of war by the Japanese during World War II. Ngauy V, Lemeshev Y, Sadkowski L, Crawford G, J Clin Microbiol 2005 43 970 972 10.1128/JCM.43.2.970-972.2005 15695721 (Pubitemid 40256075)
6. Public Health Security and Bioterrorism Preparedness and Response Act, 107th Congress. Regulations USCOF, Book Public Health Security and Bioterrorism Preparedness and Response Act, 107th Congress. vol. 42. pp. 107-118 City: Public Law 42 2002 107 118
7. The interface between innate and adaptive immunity. Hoebe K, Janssen E, Beutler B, Nat Immunol 2004 5 971 974 15454919 (Pubitemid 41057712)
8. The Immunological Basis of Acquired Cellular Resistance. Mackaness GB, J Exp Med 1964 120 105 120 10.1084/jem.120.1.105 14194388
9. Macrophage-mediated inflammation in metabolic disease. Chawla A, Nguyen KD, Goh YP, Nat Rev Immunol 2011 11 738 749 10.1038/nri3071 21984069
10. Iron in innate immunity: starve the invaders. Ganz T, Curr Opin Immunol 2009 21 63 67 10.1016/j.coi.2009.01.011 19231148
11. Protective and pathogenic functions of macrophage subsets. Murray PJ, Wynn TA, Nat Rev Immunol 2011 11 723 737 10.1038/nri3073 21997792
12. Macrophage fusion: the making of osteoclasts and giant cells. Vignery A, J Exp Med 2005 202 337 340 10.1084/jem.20051123 16061722 (Pubitemid 41126949)
13. Dynamic nature of host-pathogen interactions in Mycobacterium marinum granulomas. Bouley DM, Ghori N, Mercer KL, Falkow S, Ramakrishnan L, Infect Immun 2001 69 7820 7831 10.1128/IAI.69.12.7820-7831.2001 11705964 (Pubitemid 33086613)
14. CD4 is required for the development of a protective granulomatous response to pulmonary tuberculosis. Saunders BM, Frank AA, Orme IM, Cooper AM, Cell Immunol 2002 216 65 72 10.1016/S0008-8749(02)00510-5 12381351 (Pubitemid 35193446)
15. Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Via LE, Lin PL, Ray SM, Carrillo J, Allen SS, Eum SY, Taylor K, Klein E, Manjunatha U, Gonzales J, Lee EG, Park SK, Raleigh JA, Cho SN, McMurray DN, Flynn JL, Barry CE 3rd, Infect Immun 2008 76 2333 2340 10.1128/IAI.01515-07 18347040
16. Pulmonary tuberculosis: CT findings-early active disease and sequential change with antituberculous therapy. Im JG, Itoh H, Shim YS, Lee JH, Ahn J, Han MC, Noma S, Radiology 1993 186 653 660 8430169 (Pubitemid 23073501)
17. High resolution chest CT in tuberculosis: evolutive patterns and signs of activity. Poey C, Verhaegen F, Giron J, Lavayssiere J, Fajadet P, Duparc B, J Comput Assist Tomogr 1997 21 601 607 10.1097/00004728-199707000-00014 9216766 (Pubitemid 27432700)
18. Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Kaplan G, Post FA, Moreira AL, Wainwright H, Kreiswirth BN, Tanverdi M, Mathema B, Ramaswamy SV, Walther G, Steyn LM, Barry CE 3rd, Bekker LG, Infect Immun 2003 71 7099 7108 10.1128/IAI.71.12.7099- 7108.2003 14638800 (Pubitemid 37475342)
19. Human tuberculous granulomas induce peripheral lymphoid follicle-like structures to orchestrate local host defence in the lung. Ulrichs T, Kosmiadi GA, Trusov V, Jorg S, Pradl L, Titukhina M, Mishenko V, Gushina N, Kaufmann SH, J Pathol 2004 204 217 228 10.1002/path.1628 15376257 (Pubitemid 39335296)
20. An in vitro dual model of mycobacterial granulomas to investigate the molecular interactions between mycobacteria and human host cells. Puissegur MP, Botanch C, Duteyrat JL, Delsol G, Caratero C, Altare F, Cell Microbiol 2004 6 423 433 10.1111/j.1462-5822.2004.00371.x 15056213 (Pubitemid 38488935)
21. Fusion of hamster macrophages induced by lectins. Chambers TJ, J Pathol 1977 123 53 61 10.1002/path.1711230107 915605 (Pubitemid 8183511)
22. Interleukin-13 induces human monocyte/macrophage fusion and macrophage mannose receptor expression. DeFife KM, Jenney CR, McNally AK, Colton E, Anderson JM, J Immunol 1997 158 3385 3390 9120298 (Pubitemid 127484058)
23. Induction of multinucleated giant cell formation from in vitro culture of human monocytes with interleukin-3 and interferon-gamma: comparison with other stimulating factors. Enelow RI, Sullivan GW, Carper HT, Mandell GL, Am J Respir Cell Mol Biol 1992 6 57 62 10.1165/ajrcmb/6.1.57 1728295
24. Multinucleated giant cells generated in vitro. Terminally differentiated macrophages with down-regulated c-fms expression. Kreipe H, Radzun HJ, Rudolph P, Barth J, Hansmann ML, Heidorn K, Parwaresch MR, Am J Pathol 1988 130 232 243 2963546 (Pubitemid 18076357)
25. Anti-RMA, a murine monoclonal antibody, activates rat macrophages: II. Induction of DNA synthesis and formation of multinucleated giant cells. Lazarus D, Yamin M, McCarthy K, Schneeberger EE, Kradin R, Am J Respir Cell Mol Biol 1990 3 103 111 10.1165/ajrcmb/3.2.103 2378745
26. Interleukin 4 induces cultured monocytes/macrophages to form giant multinucleated cells. McInnes A, Rennick DM, J Exp Med 1988 167 598 611 10.1084/jem.167.2.598 3258008 (Pubitemid 18073657)
27. Anti-class II MHC antibody induces multinucleated giant cell formation from peripheral blood monocytes. Orentas RJ, Reinlib L, Hildreth JE, J Leukoc Biol 1992 51 199 209 1541903
28. Formation of multinucleated giant cells from human monocyte precursors. Mediation by a soluble protein from antigen-and mitogen-stimulated lymphocytes. Postlethwaite AE, Jackson BK, Beachey EH, Kang AH, J Exp Med 1982 155 168 178 10.1084/jem.155.1.168 7054356 (Pubitemid 12209821)
29. Kinetics and ultrastructural studies of the induction of rat alveolar macrophage fusion by mediators released from mitogen-stimulated lymphocytes. Sone S, Bucana C, Hoyer LC, Fidler IJ, Am J Pathol 1981 103 234 246 7234965 (Pubitemid 11112978)
30. Expression of fusion regulatory proteins (FRPs) on human peripheral blood monocytes. Induction of homotypic cell aggregation and formation of multinucleated giant cells by anti-FRP-1 monoclonal antibodies. Tabata N, Ito M, Shimokata K, Suga S, Ohgimoto S, Tsurudome M, Kawano M, Matsumura H, Komada H, Nishio M, Ito Y, J Immunol 1994 153 3256 3266 8089497
31. Differential regulation of formation of multinucleated giant cells from concanavalin A-stimulated human blood monocytes by IFN-gamma and IL-4. Takashima T, Ohnishi K, Tsuyuguchi I, Kishimoto S, J Immunol 1993 150 3002 3010 8454870 (Pubitemid 23127549)
32. Recombinant human gamma-interferon induces human monocyte polykaryon formation. Weinberg JB, Hobbs MM, Misukonis MA, Proc Natl Acad Sci U S A 1984 81 4554 4557 10.1073/pnas.81.14.4554 6431409 (Pubitemid 14055930)
33. Multinucleate giant cells. Chambers TJ, J Pathol 1978 126 125 148 10.1002/path.1711260302 370353 (Pubitemid 9062597)
34. Cytokine-induced generation of multinucleated giant cells in vitro requires interferon-gamma and expression of LFA-1. Most J, Neumayer HP, Dierich MP, Eur J Immunol 1990 20 1661 1667 10.1002/eji.1830200807 1976520 (Pubitemid 20290897)
35. The CC chemokine ligand, CCL2/MCP1, participates in macrophage fusion and foreign body giant cell formation. Kyriakides TR, Foster MJ, Keeney GE, Tsai A, Giachelli CM, Clark-Lewis I, Rollins BJ, Bornstein P, Am J Pathol 2004 165 2157 2166 10.1016/S0002-9440(10)63265-8 15579457 (Pubitemid 39578392)
36. DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. Yagi M, Miyamoto T, Sawatani Y, Iwamoto K, Hosogane N, Fujita N, Morita K, Ninomiya K, Suzuki T, Miyamoto K, Oike Y, Takeya M, Toyama Y, Suda T, J Exp Med 2005 202 345 351 10.1084/jem.20050645 16061724 (Pubitemid 41126951)
37. Molecular mediators of macrophage fusion. Helming L, Gordon S, Trends Cell Biol 2009 19 514 522 10.1016/j.tcb.2009.07.005 19733078
38. Foreign body giant cell formation is preceded by lamellipodia formation and can be attenuated by inhibition of Rac1 activation. Jay SM, Skokos E, Laiwalla F, Krady MM, Kyriakides TR, Am J Pathol 2007 171 632 640 10.2353/ajpath.2007.061213 17556592 (Pubitemid 47344695)
39. Essential role of DAP12 signaling in macrophage programming into a fusion-competent state. Helming L, Tomasello E, Kyriakides TR, Martinez FO, Takai T, Gordon S, Vivier E, Sci Signal 2008 1 a11 18957693
40. The scavenger receptor CD36 plays a role in cytokine-induced macrophage fusion. Helming L, Winter J, Gordon S, J Cell Sci 2009 122 453 459 10.1242/jcs.037200 19155290
41. Macrophage fusion, giant cell formation, and the foreign body response require matrix metalloproteinase 9. MacLauchlan S, Skokos EA, Meznarich N, Zhu DH, Raoof S, Shipley JM, Senior RM, Bornstein P, Kyriakides TR, J Leukoc Biol 2009 85 617 626 10.1189/jlb.1008588 19141565
42. Alternatively activated macrophages engage in homotypic and heterotypic interactions through IL-4 and polyamine-induced E-cadherin/catenin complexes. Van den Bossche J, Bogaert P, Van Hengel J, Guerin CJ, Berx G, Movahedi K, Van den Bergh R, Pereira-Fernandes A, Geuns JM, Pircher H, Dorny P, Grooten J, De Baetselier P, Van Ginderachter JA, Blood 2009 114 4664 4674 10.1182/blood-2009- 05-221598 19726720
43. NF-kappaB signaling participates in both RANKL- and IL-4-induced macrophage fusion: receptor cross-talk leads to alterations in NF-kappaB pathways. Yu M, Qi X, Moreno JL, Farber DL, Keegan AD, J Immunol 2011 187 1797 1806 10.4049/jimmunol.1002628 21734075
44. Dissection of the Burkholderia intracellular life cycle using a photothermal nanoblade. French CT, Toesca IJ, Wu TH, Teslaa T, Beaty SM, Wong W, Liu M, Schroder I, Chiou PY, Teitell MA, Miller JF, Proc Natl Acad Sci U S A 2011 108 12095 12100 10.1073/pnas.1107183108 21730143
45. Quorum sensing negatively regulates multinucleate cell formation during intracellular growth of Burkholderia pseudomallei in macrophage-like cells. Horton RE, Grant GD, Matthews B, Batzloff M, Owen SJ, Kyan S, Flegg CP, Clark AM, Ulett GC, Morrison N, Peak IR, Beacham IR, PLoS One 2013 8 63394 10.1371/journal.pone.0063394 23704903
46. Burkholderia pseudomallei induces cell fusion and actin-associated membrane protrusion: a possible mechanism for cell-to-cell spreading. Kespichayawattana W, Rattanachetkul S, Wanun T, Utaisincharoen P, Sirisinha S, Infect Immun 2000 68 5377 5384 10.1128/IAI.68.9.5377-5384.2000 10948167
47. The histopathology of human melioidosis. Wong KT, Puthucheary SD, Vadivelu J, Histopathology 1995 26 51 55 10.1111/j.1365-2559.1995.tb00620.x 7713483
48. The bacterial gene lfpA influences the potent induction of calcitonin receptor and osteoclast-related genes in Burkholderia pseudomallei-induced TRAP-positive multinucleated giant cells. Boddey JA, Day CJ, Flegg CP, Ulrich RL, Stephens SR, Beacham IR, Morrison NA, Peak IR, Cell Microbiol 2007 9 514 531 10.1111/j.1462-5822.2006.00807.x 16987331 (Pubitemid 46092176)
49. iNOS activity is critical for the clearance of Burkholderia mallei from infected RAW 264.7 murine macrophages. Brett PJ, Burtnick MN, Su H, Nair V, Gherardini FC, Cell Microbiol 2008 10 487 498 17970762
50. Burkholderia pseudomallei type III secretion system mutants exhibit delayed vacuolar escape phenotypes in RAW 264.7 murine macrophages. Burtnick MN, Brett PJ, Nair V, Warawa JM, Woods DE, Gherardini FC, Infect Immun 2008 76 2991 3000 10.1128/IAI.00263-08 18443088
51. Effects of Burkholderia pseudomallei and other Burkholderia species on eukaryotic cells in tissue culture. Harley VS, Dance DA, Drasar BS, Tovey G, Microbios 1998 96 71 93 10093229 (Pubitemid 128557789)
52. Identification of Burkholderia pseudomallei genes required for the intracellular life cycle and in vivo virulence. Pilatz S, Breitbach K, Hein N, Fehlhaber B, Schulze J, Brenneke B, Eberl L, Steinmetz I, Infect Immun 2006 74 3576 3586 10.1128/IAI.01262-05 16714590 (Pubitemid 43794549)
53. Multinucleated giant cell formation and apoptosis in infected host cells is mediated by Burkholderia pseudomallei type III secretion protein BipB. Suparak S, Kespichayawattana W, Haque A, Easton A, Damnin S, Lertmemongkolchai G, Bancroft GJ, Korbsrisate S, J Bacteriol 2005 187 6556 6560 10.1128/JB.187.18.6556-6560.2005 16159789 (Pubitemid 41318415)
54. An Account of a Glanders-like Disease occurring in Rangoon. Whitmore A, J Hyg 1913 13 1 34 31 10.1017/S0022172400005234
55. Type VI secretion is a major virulence determinant in Burkholderia mallei. Schell MA, Ulrich RL, Ribot WJ, Brueggemann EE, Hines HB, Chen D, Lipscomb L, Kim HS, Mrazek J, Nierman WC, Deshazer D, Mol Microbiol 2007 64 1466 1485 10.1111/j.1365-2958.2007.05734.x 17555434 (Pubitemid 46889897)
56. In vivo expression technology identifies a type VI secretion system locus in Burkholderia pseudomallei that is induced upon invasion of macrophages. Shalom G, Shaw JG, Thomas MS, Microbiology 2007 153 2689 2699 10.1099/mic.0.2007/006585-0 17660433 (Pubitemid 47262058)
57. Inactivation of Burkholderia pseudomallei bsaQ results in decreased invasion efficiency and delayed escape of bacteria from endocytic vesicles. Muangsombut V, Suparak S, Pumirat P, Damnin S, Vattanaviboon P, Thongboonkerd V, Korbsrisate S, Arch Microbiol 2008 190 623 631 10.1007/s00203-008-0413-3 18654761
58. The cluster 1 type VI secretion system is a major virulence determinant in Burkholderia pseudomallei. Burtnick MN, Brett PJ, Harding SV, Ngugi SA, Ribot WJ, Chantratita N, Scorpio A, Milne TS, Dean RE, Fritz DL, Peacock SJ, Prior JL, Atkins TP, Deshazer D, Infect Immun 2011 79 1512 1525 10.1128/IAI.01218-10 21300775
59. Burkholderia pseudomallei RpoS regulates multinucleated giant cell formation and inducible nitric oxide synthase expression in mouse macrophage cell line (RAW 264.7). Utaisincharoen P, Arjcharoen S, Limposuwan K, Tungpradabkul S, Sirisinha S, Microb Pathog 2006 40 184 189 10.1016/j.micpath. 2006.01.002 16524693
60. The T6SS-5 VgrG spike protein mediates membrane fusion during intercellular spread by pseudomallei-group Burkholderia species. Toesca IJ, French CT, Miller JF, Infect Immun 2014 82 1436 1444 10.1128/IAI.01367-13 24421040
61. Microscopic imaging techniques for drug discovery. Bullen A, Nat Rev Drug Discov 2008 7 54 67 10.1038/nrd2446 18079755
62. High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors. Christophe T, Jackson M, Jeon HK, Fenistein D, Contreras-Dominguez M, Kim J, Genovesio A, Carralot JP, Ewann F, Kim EH, Lee SY, Kang S, Seo MJ, Park EJ, Skovierova H, Pham H, Riccardi G, Nam JY, Marsollier L, Kempf M, Joly-Guillou ML, Oh T, Shin WK, No Z, Nehrbass U, Brosch R, Cole ST, Brodin P, PLoS Pathog 2009 5 1000645 10.1371/journal.ppat.1000645 19876393
63. A loss-of-function screen reveals Ras- and Raf-independent MEK-ERK signaling during Chlamydia trachomatis infection. Gurumurthy RK, Maurer AP, Machuy N, Hess S, Pleissner KP, Schuchhardt J, Rudel T, Meyer TF, Sci Signal 2010 3 a21 20234004
64. Cellular imaging in drug discovery. Lang P, Yeow K, Nichols A, Scheer A, Nat Rev Drug Discov 2006 5 343 356 10.1038/nrd2008 16582878
65. Prioritizing hits from phenotypic high-content screens. Low J, Stancato L, Lee J, Sutherland JJ, Curr Opin Drug Discov Devel 2008 11 338 345 18428087 (Pubitemid 351572443)
66. RNAi screen of Salmonella invasion shows role of COPI in membrane targeting of cholesterol and Cdc42. Misselwitz B, Dilling S, Vonaesch P, Sacher R, Snijder B, Schlumberger M, Rout S, Stark M, Von Mering C, Pelkmans L, Hardt WD, Mol Syst Biol 2011 7 474 21407211
67. Multidimensional drug profiling by automated microscopy. Perlman ZE, Slack MD, Feng Y, Mitchison TJ, Wu LF, Altschuler SJ, Science 2004 306 1194 1198 10.1126/science.1100709 15539606 (Pubitemid 39489001)
68. An unbiased cell morphology-based screen for new, biologically active small molecules. Tanaka M, Bateman R, Rauh D, Vaisberg E, Ramachandani S, Zhang C, Hansen KC, Burlingame AL, Trautman JK, Shokat KM, Adams CL, PLoS Biol 2005 3 128 10.1371/journal.pbio.0030128 15799708 (Pubitemid 40958400)
69. Integrating high-content screening and ligand-target prediction to identify mechanism of action. Young DW, Bender A, Hoyt J, McWhinnie E, Chirn GW, Tao CY, Tallarico JA, Labow M, Jenkins JL, Mitchison TJ, Feng Y, Nat Chem Biol 2008 4 59 68 10.1038/nchembio.2007.53 18066055 (Pubitemid 350273652)
70. Type III secretion system cluster 3 is required for maximal virulence of Burkholderia pseudomallei in a hamster infection model. Warawa J, Woods DE, FEMS Microbiol Lett 2005 242 101 108 10.1016/j.femsle.2004.10.045 15621426 (Pubitemid 40038426)
71. Epigenetics and bacterial infections. Bierne H, Hamon M, Cossart P, Cold Spring Harbor Perspectives in Medicine 2012 2 010272 23209181
72. In vitro antibiotic susceptibilities of Burkholderia mallei (causative agent of glanders) determined by broth microdilution and E-test. Heine HS, England MJ, Waag DM, Byrne WR, Antimicrob Agents Chemother 2001 45 2119 2121 10.1128/AAC.45.7.2119-2121.2001 11408233 (Pubitemid 32591708)
73. Preparation of genomic DNA from bacteria. Wilson K, Curr Protoc Mol Biol 2001 00 2.4.1 2.4.5
74. An allelic exchange system for compliant genetic manipulation of the select agents Burkholderia pseudomallei and Burkholderia mallei. Hamad MA, Zajdowicz SL, Holmes RK, Voskuil MI, Gene 2009 430 123 131 10.1016/j.gene.2008. 10.011 19010402
75. Mutagenesis of Burkholderia pseudomallei with Tn5-OT182: isolation of motility mutants and molecular characterization of the flagellin structural gene. DeShazer D, Brett PJ, Carlyon R, Woods DE, J Bacteriol 1997 179 2116 2125 9079894 (Pubitemid 27146863)
76. Aerogenic vaccination with a Burkholderia mallei auxotroph protects against aerosol-initiated glanders in mice. Ulrich RL, Amemiya K, Waag DM, Roy CJ, DeShazer D, Vaccine 2005 23 1986 1992 10.1016/j.vaccine.2004.10.017 15734072 (Pubitemid 40289071)